KEGG   DRUG: Tisotumab vedotin
Entry
D11814                      Drug                                   
Name
Tisotumab vedotin (USAN/INN);
Tisotumab vedotin (genetical recombination) (JAN);
Tisotumab vedotin-tftv;
Tivdak (TN)
Product
Formula
C6418H9906N1710O2022S44.(C68H106N11O15)n
Remark
ATC code: L01FX23
Product: D11814<US>
Efficacy
Antineoplastic
  Disease
Cervical cancer [DS:H00030]
  Type
Antibody-drug conjugate
Target
F3 (CD142) [HSA:2152] [KO:K03901]
TUBB [HSA:10381 10382 10383 203068 347688 347733 7280 81027 84617] [KO:K07375]
  Pathway
hsa04540  Gap junction
hsa04610  Complement and coagulation cascades
hsa04933  AGE-RAGE signaling pathway in diabetic complications
Interaction
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
  L01 ANTINEOPLASTIC AGENTS
   L01F MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
    L01FX Other monoclonal antibodies and antibody drug conjugates
     L01FX23 Tisotumab vedotin
      D11814  Tisotumab vedotin (USAN/INN) <US>
USP drug classification [BR:br08302]
 Antineoplastics
  Monoclonal Antibody/Antibody-Drug Conjugate
   Tisotumab Vedotin
    D11814  Tisotumab vedotin (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    F3 (CD142)
     D11814  Tisotumab vedotin (USAN/INN) <US>
 Not elsewhere classified
  Cellular process
   Cytoskeleton
    TUBB
     D11814  Tisotumab vedotin (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11814
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11814
Other DBs
CAS: 1418731-10-8
PubChem: 405226679

» Japanese version   » Back

DBGET integrated database retrieval system